Is Egrifta (Tesamorelin) Legal in Georgia?

Federal Legal Status of Tesamorelin

Egrifta (tesamorelin) holds full FDA approval and is dispensed as a Schedule-free prescription drug in the United States. It is not classified as a controlled substance under the Controlled Substances Act, which means neither the DEA nor Georgia imposes scheduling restrictions on its prescription or possession when obtained through a licensed channel.

FDA Approval History

The FDA approved tesamorelin acetate under NDA 022505 on November 10, 2010, for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Theratechnologies Inc. holds the approved new drug application. A supplemental approval for a newer formulation, Egrifta SV, followed in 2019, providing a stabilized preparation that does not require refrigeration after first use. Because tesamorelin is an FDA-approved drug product, it occupies a well-defined legal category: it is a prescription medication subject to the Federal Food, Drug, and Cosmetic Act (FDCA), not a research chemical or gray-market peptide. [1]

Why Federal Status Determines Most of the Legal Picture

Georgia does not maintain a separate state-level formulary that overrides FDA scheduling decisions for peptides like tesamorelin. The state's drug law framework, codified in O.C.G.A. Title 26 (Food, Drugs, and Cosmetics), largely mirrors federal standards. If a drug is federally approved and not federally scheduled, Georgia treats it as a prescription drug requiring a valid prescriber-patient relationship, not as a controlled or prohibited substance. [2]

That distinction matters in practice. A patient who obtains tesamorelin through a legitimate physician prescription and a registered pharmacy is on solid legal ground under both federal and Georgia state law.

Georgia State Pharmacy and Medical Practice Framework

Georgia regulates the dispensing of prescription drugs through two overlapping bodies: the Georgia State Board of Pharmacy and the Georgia Composite Medical Board. Both operate under the Georgia Secretary of State's Professional Licensing Boards Division.

Georgia State Board of Pharmacy

The Georgia State Board of Pharmacy licenses pharmacies and pharmacists under O.C.G.A. Title 26, Chapter 4. Any pharmacy dispensing Egrifta to a Georgia patient must hold a valid Georgia pharmacy license. Out-of-state mail-order pharmacies that ship branded Egrifta into Georgia are required to hold a non-resident pharmacy permit issued by the Georgia Board. [3]

Dispensing tesamorelin outside that framework, for example purchasing a raw peptide labeled "for research use only" from an unregistered supplier, is not authorized and may violate both federal FDCA provisions and Georgia's pharmacy practice act.

Georgia Composite Medical Board

Georgia physicians, nurse practitioners, and physician assistants who prescribe Egrifta must hold an active Georgia license. Off-label prescribing of FDA-approved drugs is legal and within the standard scope of medical practice in Georgia, consistent with guidance from the American Academy of Family Physicians. [4] A prescriber who writes for tesamorelin for a non-HIV indication, such as age-related growth hormone deficiency or body composition in non-HIV adults, is exercising legal off-label prescribing authority, though off-label use is not supported by FDA-reviewed efficacy data for those populations.

Telehealth Prescribing in Georgia

Georgia's Telehealth Act (O.C.G.A. 33-24-56.4) and subsequent regulatory updates permit prescribers to establish patient-prescriber relationships via synchronous audio-video visits. Once that relationship exists, a prescriber may issue a tesamorelin prescription electronically. The prescription must comply with standard Georgia e-prescribing requirements, and the dispensing pharmacy must be properly registered. Telehealth platforms that connect Georgia patients to licensed prescribers for hormonal therapies, including Egrifta, operate lawfully when they meet those conditions.

Compounding and the 503A / 503B Gray Area

This is where the legal picture becomes genuinely complicated for patients who have seen tesamorelin offered at lower cost through compounding pharmacies.

What 503A and 503B Pharmacies Can and Cannot Do

Under the FDCA, a 503A pharmacy (traditional compounding) may prepare a drug product that is not a copy of an FDA-approved product, uses bulk drug substances that appear on the FDA's approved bulk list, and is prepared pursuant to a valid patient-specific prescription. A 503B outsourcing facility operates under stricter cGMP standards and may produce larger batches without individual prescriptions but still must use approved bulk substances.

The critical issue for tesamorelin: tesamorelin is not listed on the FDA's 503A Bulk Drug Substances list (the so-called "Category 1" list). [5] Because it is also an active ingredient in an FDA-approved product (Egrifta), compounding pharmacies face a significant legal constraint. The FDA's general position is that compounding a drug that is a copy of, or essentially a copy of, an approved product raises concerns under FDCA Section 503A(b)(1)(D) and may constitute unlawful manufacturing. [6]

In practical terms, this means:

• Branded Egrifta obtained via a legitimate prescription: clearly legal.
• Compounded tesamorelin from a 503A or 503B pharmacy: in a legally ambiguous position and potentially outside FDA compliance, regardless of state.
• Raw tesamorelin peptide purchased online labeled "not for human use": not a legal path to medical treatment in Georgia or any other state.

What Georgia Patients Should Do

Georgia's Board of Pharmacy has not issued a state-specific opinion that expands 503A access to tesamorelin beyond the federal framework. If a Georgia patient sees a compounding pharmacy offering tesamorelin at lower cost, they should ask the pharmacy to document its compliance basis under federal FDCA Section 503A or 503B. A reputable compounding pharmacy will answer that question directly.

The HealthRX editorial team uses a four-question compliance checklist for any peptide prescription in a state like Georgia where federal law is the primary framework:

1. Is the molecule FDA-approved as a finished drug product? (Tesamorelin: Yes, as Egrifta.)
2. Is the molecule on the DEA controlled substances schedule? (Tesamorelin: No.)
3. Is the dispensing pharmacy licensed in the patient's state or holding a non-resident permit? (Must verify per order.)
4. If compounded, is the bulk substance on the FDA's 503A or 503B approval list? (Tesamorelin: Not confirmed on current lists; verify with pharmacy.)

A "yes" to questions 1 and 3, "no" to question 2, and a documented answer to question 4 provides the clearest path to legal, safe dispensing for a Georgia patient.

Clinical Evidence Supporting Tesamorelin

Understanding why Egrifta carries FDA approval helps patients ask better questions of their prescribers. The approval rests on two phase 3 trials conducted in HIV-infected adults with abdominal lipodystrophy.

LIPO-010 and LIPO-011 Key Trials

In the LIPO-010 trial (N=412), tesamorelin 2 mg/day subcutaneously for 26 weeks produced a mean 18% reduction in visceral adipose tissue (VAT) area versus 1% in the placebo group (P<0.001). [7] The LIPO-011 trial replicated these findings with a similar effect size across a comparable population. These data formed the evidentiary basis for FDA approval and are summarized in the prescribing information for Egrifta.

A 52-week extension study showed that VAT reduction was maintained with continued therapy and largely reversed when treatment was stopped, which informs real-world prescribing: patients who discontinue tesamorelin typically see fat redistribution return within 12 weeks. [8]

IGF-1 Monitoring and Safety Parameters

Tesamorelin acts as a growth hormone releasing factor (GHRF) analog. It stimulates pulsatile GH release, which raises insulin-like growth factor-1 (IGF-1) levels. The Egrifta prescribing information recommends IGF-1 monitoring during therapy because supraphysiologic IGF-1 carries theoretical risks including glucose intolerance and, in the context of pre-existing malignancy, potential tumor growth promotion. [9] The FDA-approved labeling states: "Tesamorelin is contraindicated in patients with active malignancy."

Clinicians prescribing Egrifta in Georgia are expected to perform baseline and periodic IGF-1 testing, glucose monitoring, and evaluation for contraindications consistent with the FDA-approved prescribing information and the Endocrine Society's clinical practice guidelines on adult growth hormone deficiency. [10]

Off-Label Evidence

The evidence for tesamorelin outside HIV-associated lipodystrophy is emerging but not yet sufficient for FDA approval in other populations. One randomized trial published in the Journal of the American Medical Association (JAMA) examined tesamorelin in older adults without HIV and found modest but statistically significant reductions in VAT at 6 months compared to placebo. [11] Georgia prescribers who use tesamorelin off-label for age-related body composition changes are making a clinical judgment that the existing data supports the benefit-risk ratio for their specific patient. That judgment is legal. Whether it is covered by insurance is a separate question.

How to Get a Tesamorelin Prescription in Georgia

Getting Egrifta in Georgia follows the same pathway as any other brand-name prescription drug.

Step 1: Establish Care with a Licensed Prescriber

A Georgia-licensed physician, nurse practitioner, or physician assistant must evaluate the patient. That evaluation can occur in person or via a telehealth video visit. The prescriber will review the patient's HIV status (for FDA-approved use), body composition, metabolic labs including fasting glucose and HbA1c, IGF-1 baseline, and contraindications such as active malignancy, pregnancy, or pituitary disease.

Step 2: Receive a Valid Prescription

The prescriber issues a written or electronic prescription for Egrifta (tesamorelin acetate) 2 mg/day subcutaneous injection. The prescription must meet Georgia's standard prescription requirements including the prescriber's DEA number (even though tesamorelin is not scheduled, DEA registration is standard on all Georgia prescriptions), patient date of birth, and drug name, strength, and quantity.

Step 3: Fill at a Licensed Pharmacy

Branded Egrifta is dispensed through specialty pharmacies. Theratechnologies operates a patient assistance program (Egrifta Forward) for patients who qualify based on income and insurance status. Several national specialty pharmacies hold Georgia non-resident permits and ship Egrifta directly to Georgia patients with valid prescriptions. The patient is responsible for confirming the pharmacy holds a current Georgia non-resident pharmacy permit or a full Georgia pharmacy license.

Step 4: Storage and Administration

Egrifta SV (the current formulation) is supplied as a lyophilized powder that must be reconstituted with the provided diluent. After first use, Egrifta SV may be stored at room temperature (up to 77°F) for up to 3 months. The standard reconstituted dose of 2 mg is injected subcutaneously into the abdomen once daily, rotating injection sites. Patients should not inject into scar tissue, the navel, or bruised areas.

Insurance Coverage and Cost in Georgia

Egrifta is expensive. Without insurance, retail cost in Georgia runs approximately $3,000 to $5,000 per month depending on the pharmacy. For HIV-positive patients with a documented lipodystrophy diagnosis, most major commercial insurance plans and Georgia Medicaid cover Egrifta after prior authorization. Coverage for off-label use is substantially harder to obtain and typically requires documented failure of lifestyle modification and supporting clinical notes.

Theratechnologies' Egrifta Forward program can reduce out-of-pocket costs for commercially insured patients to as low as $0 per month for eligible individuals. Uninsured Georgia patients with income at or below 400% of the federal poverty level may qualify for free drug through the manufacturer's patient assistance program.

Legal Risks to Avoid in Georgia

Three patterns put Georgia patients at legal or clinical risk even when they believe they are acting lawfully.

First, purchasing tesamorelin from overseas online pharmacies and importing it for personal use. The FDA's personal importation policy does not protect drug products that lack FDA approval in their specific manufactured form, and peptides sold by international research suppliers almost never carry FDA approval for human use. [12]

Second, obtaining compounded tesamorelin without verifying the pharmacy's 503A or 503B compliance documentation. The lower price often reflects the legal ambiguity, not equivalent pharmaceutical quality. Compounded peptides are not subject to the same purity, potency, and sterility testing as branded Egrifta.

Third, sharing or selling a tesamorelin prescription with another person. Tesamorelin is not a DEA-scheduled substance, but transferring a prescription drug to a person for whom it was not prescribed violates Georgia's pharmacy practice act and federal law.